litlas
Log inCreate account

Martin Rowe

Active 1979–2019

94
Papers
18,308
Citations
83
h-index
93
i10-index

Citations

Citations per year for Martin Rowe1981: 2 citations1982: 3 citations1983: 2 citations1984: 6 citations1985: 15 citations1986: 28 citations1987: 64 citations1988: 65 citations1989: 77 citations1990: 79 citations1991: 172 citations1992: 214 citations1993: 261 citations1994: 193 citations1995: 264 citations1996: 225 citations1997: 227 citations1998: 185 citations1999: 239 citations2000: 196 citations2001: 193 citations2002: 178 citations2003: 161 citations2004: 114 citations2005: 93 citations2006: 114 citations2007: 110 citations2008: 87 citations2009: 121 citations2010: 100 citations2011: 87 citations2012: 81 citations2013: 86 citations2014: 154 citations2015: 141 citations2016: 93 citations2017: 102 citations2018: 75 citations2019: 225 citations2020: 198 citations2021: 245 citations2022: 147 citations2023: 144 citations2024: 162 citations2025: 66 citations2026: 1 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,524 citing papers, 32.8% of this breakdownUnited Kingdom: 542 citing papers, 11.7% of this breakdownGermany: 370 citing papers, 8% of this breakdownChina: 247 citing papers, 5.3% of this breakdownJapan: 188 citing papers, 4.1% of this breakdownFrance: 180 citing papers, 3.9% of this breakdownItaly: 160 citing papers, 3.4% of this breakdownAustralia: 146 citing papers, 3.1% of this breakdownNetherlands: 119 citing papers, 2.6% of this breakdownCanada: 118 citing papers, 2.5% of this breakdownSweden: 114 citing papers, 2.5% of this breakdownSwitzerland: 84 citing papers, 1.8% of this breakdown
0%32.8%Other 18.3%

Institutions

Fields

  • Medicine68.8%
  • Biochemistry, Genetics and Molecular Biology18.3%
  • Immunology and Microbiology11.2%
  • Agricultural and Biological Sciences0.6%
  • Neuroscience0.4%
  • Environmental Science0.2%
  • Other0.5%

Topics

  • Viral-associated cancers and disorders17.7%
  • Lymphoma Diagnosis and Treatment10.5%
  • Immune Cell Function and Interaction6.6%
  • Cytomegalovirus and herpesvirus research5.4%
  • Parvovirus B19 Infection Studies4%
  • Herpesvirus Infections and Treatments2.3%
  • Other53.5%

Coauthors

All papers

Open in search
  1. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

    Authors: Roland Schmitz, Ryan M. Young, Michele Ceribelli, Sameer Jhavar, Wenming Xiao, Meili Zhang, George W. Wright, Arthur L. Shaffer, Daniel J. Hodson, Eric D. Buras, Xuelu Liu, John Powell, Yandan Yang, Weihong Xu, Hong Zhao, Holger Kohlhammer, Andreas Rosenwald, Philip M. Kluin, Hans Konrad Müller‐Hermelink, German Ott, Randy D. Gascoyne, Joseph M. Connors, Lisa M. Rimsza, Elı́as Campo, Elaine S. Jaffe, Jan Delabie, Erlend B. Smeland, Martin D. Ogwang, Steven J. Reynolds, Richard I. Fisher, Rita M. Braziel, Raymond R. Tubbs, James R. Cook, Dennis D. Weisenburger, Wing C. Chan, Stefania Pittaluga, Wyndham H. Wilson, Thomas A. Waldmann, Martin Rowe, Sam M. Mbulaiteye, Alan B. Rickinson, Louis M. Staudt - Nature 2012 cited by 920

  2. Host shutoff during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion

    Authors: Martin Rowe, Britt A. Glaunsinger, Daphne van Leeuwen, Jianmin Zuo, David A. Sweetman, Don Ganem, Jaap M. Middeldorp, Emmanuel J. H. J. Wiertz, Maaike E. Ressing - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 246

  3. EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins

    Authors: Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura C.A. Galbraith, Chathura D. Suraweera, Deborah Croom‐Carter, Grant Dewson, Rosemary J. Tierney, Andrew Bell, C. Shannon‐Lowe, Marco J. Herold, Alan B. Rickinson, Peter M. Colman, David C.S. Huang, Andreas Strasser, Marc Kvansakul, Martin Rowe, Gemma L. Kelly - Cell Death and Differentiation 2019 cited by 63

  4. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II

    Authors: Laura L. Quinn, Luke Williams, Claire White, Calum Forrest, Jianmin Zuo, Martin Rowe - Journal of Virology 2015 cited by 91

  5. The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation

    Authors: Jianmin Zuo, Andrew Currin, Bryan D. Griffin, Claire Shannon‐Lowe, Wendy A. Thomas, Maaike E. Ressing, Emmanuel J. H. J. Wiertz, Martin Rowe - PLoS Pathogens 2009 cited by 207

  6. Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion

    Authors: Maaike E. Ressing, Daphne van Leeuwen, Frank A. W. Verreck, Sinéad E. Keating, Raquel Gomez, Kees L. M. C. Franken, Tom H. M. Ottenhoff, Melanie K. Spriggs, Ton N. Schumacher, Lindsey Hutt‐Fletcher, Martin Rowe, Emmanuel J. H. J. Wiertz - Journal of Virology 2004 cited by 100

  7. Epstein Barr virus entry; kissing and conjugation

    Authors: Claire Shannon‐Lowe, Martin Rowe - Current Opinion in Virology 2014 cited by 84

  8. Epstein-Barr Virus Infection of Polarized Epithelial Cells via the Basolateral Surface by Memory B Cell-Mediated Transfer Infection

    Authors: Claire Shannon‐Lowe, Martin Rowe - PLoS Pathogens 2011 cited by 118

  9. An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link

    Authors: Gemma L. Kelly, Heather M. Long, Julianna Stylianou, Wendy A. Thomas, Alison M. Leese, Andrew Bell, Georg W. Bornkamm, Josef Mautner, Alan B. Rickinson, Martin Rowe - PLoS Pathogens 2009 cited by 172

  10. Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products

    Authors: Maaike E. Ressing, Daniëlle Horst, Bryan D. Griffin, Judy Tellam, Jianmin Zuo, Rajiv Khanna, Martin Rowe, Emmanuel J. H. J. Wiertz - Seminars in Cancer Biology 2008 cited by 127

  11. Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death

    Authors: S. A. Henderson, Martin Rowe, C D Gregory, Debbie Croom-Carter, Fred Wang, Richard Longnecker, Elliott Kieff, Alan B. Rickinson - Cell 1991 cited by 1,189

  12. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death.

    Authors: S. A. Henderson, David Huen, Martin Rowe, Chris Dawson, George S. Johnson, Alan B. Rickinson - National Academy of Sciences, Proceedings of the National Academy of Sciences 1993 cited by 602

  13. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain.

    Authors: David Huen, S A Henderson, Debbie Croom-Carter, Martin Rowe - 1995 cited by 463

  14. HLA-A11 Epitope Loss Isolates of Epstein-Barr Virus From a Highly A11 + Population

    Authors: Pedro O. de Campos‐Lima, Riccardo Gavioli, Qian-Jin Zhang, Lesley E. Wallace, Riccardo Dolcetti, Martin Rowe, Alan B. Rickinson, Maria G. Masucci - Science 1993 cited by 258

  15. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers

    Authors: Martin Rowe, M. Peng-Pilon, David Huen, Rich Hardy, Debbie Croom-Carter, Erik Lundgren, Alan B. Rickinson - Journal of Virology 1994 cited by 202

  16. The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways

    Authors: Jianmin Zuo, Laura L. Quinn, Jennifer Tamblyn, Wendy A. Thomas, Regina Feederle, Henri‐Jacques Delecluse, Andrew D. Hislop, Martin Rowe - Journal of Virology 2010 cited by 95

  17. Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle

    Authors: Nathan P. Croft, Claire Shannon‐Lowe, Andrew Bell, Daniëlle Horst, Elisabeth Kremmer, Maaike E. Ressing, Emmanuel J. H. J. Wiertz, Jaap M. Middeldorp, Martin Rowe, Alan B. Rickinson, Andrew D. Hislop - PLoS Pathogens 2009 cited by 95

  18. Epstein-Barr virus and Burkitt lymphoma

    Authors: Martin Rowe, Leah Fitzsimmons, Andrew Bell - Chinese Journal of Cancer 2014 cited by 83

  19. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

    Authors: R J Murray, Michael G. Kurilla, Jill Brooks, Wendy A. Thomas, Martin Rowe, E Kieff, Alan B. Rickinson - The Journal of Experimental Medicine 1992 cited by 506

  20. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

    Authors: F Wang, Christopher D. Gregory, Martin Rowe, A. B. Rickinson, D Wang, Mark Birkenbach, Hitoshi Kikutani, Tadamitsu Kishimoto, Elliott Kieff - National Academy of Sciences, Proceedings of the National Academy of Sciences 1987 cited by 392

  21. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes

    Authors: Martin Rowe, Andrea Lear, Debbie Croom-Carter, Adam Davies, Alan B. Rickinson - Journal of Virology 1992 cited by 358

  22. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line

    Authors: C D Gregory, Martin Rowe, Alan B. Rickinson - Journal of General Virology 1990 cited by 339

  23. Epstein – Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors

    Authors: Aristides G. Eliopoulos, Maria Stack, William O. Dawson, Kenneth M. Kaye, Liz Hodgkin, Sim K. Sihota, Martin Rowe, Lawrence S. Young - Oncogene 1997 cited by 258

  24. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

    Authors: Gemma L. Kelly, Stephanie Grabow, Stefan Glaser, Leah Fitzsimmons, Brandon J. Aubrey, Toru Okamoto, Liz J. Valente, Mikara Robati, Lin Tai, W. Douglas Fairlie, Erinna F. Lee, Mikael S. Lindström, Klas G. Wiman, David C.S. Huang, Philippe Bouillet, Martin Rowe, Alan B. Rickinson, Marco J. Herold, Andreas Strasser - Genes & Development 2014 cited by 169